CareDx, Inc (NASDAQ:CDNA) Director Sells $18,005.00 in Stock

CareDx, Inc (NASDAQ:CDNAGet Rating) Director Michael Goldberg sold 500 shares of CareDx stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $36.01, for a total value of $18,005.00. Following the completion of the sale, the director now directly owns 62,267 shares in the company, valued at $2,242,234.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Goldberg also recently made the following trade(s):

  • On Wednesday, March 9th, Michael Goldberg sold 500 shares of CareDx stock. The stock was sold at an average price of $33.41, for a total value of $16,705.00.
  • On Wednesday, February 9th, Michael Goldberg sold 500 shares of CareDx stock. The stock was sold at an average price of $42.96, for a total value of $21,480.00.

NASDAQ:CDNA traded up $0.75 during trading hours on Wednesday, reaching $38.02. The company had a trading volume of 671,423 shares, compared to its average volume of 698,388. CareDx, Inc has a 1-year low of $27.87 and a 1-year high of $96.88. The firm has a market cap of $2.02 billion, a PE ratio of -64.44 and a beta of 0.68. The business’s 50 day moving average price is $38.00 and its 200-day moving average price is $45.54.

CareDx (NASDAQ:CDNAGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.12). CareDx had a negative net margin of 10.35% and a negative return on equity of 6.49%. The company had revenue of $79.22 million during the quarter, compared to analyst estimates of $78.10 million. During the same period in the previous year, the firm posted ($0.07) earnings per share. The company’s revenue was up 35.1% compared to the same quarter last year. On average, equities analysts anticipate that CareDx, Inc will post -0.92 earnings per share for the current year.

Several equities research analysts have weighed in on CDNA shares. Craig Hallum reduced their price objective on CareDx from $106.00 to $87.00 in a research note on Friday, February 25th. BTIG Research cut their price target on CareDx from $100.00 to $65.00 in a research note on Monday, February 28th. Raymond James cut their price target on CareDx from $90.00 to $52.00 and set a “strong-buy” rating on the stock in a research note on Friday, February 25th. Zacks Investment Research lowered CareDx from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 13th. Finally, StockNews.com lowered CareDx from a “hold” rating to a “sell” rating in a research note on Friday, April 8th. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, CareDx currently has an average rating of “Buy” and an average price target of $81.80.

A number of large investors have recently made changes to their positions in CDNA. Putnam Investments LLC purchased a new stake in shares of CareDx in the third quarter valued at approximately $1,448,000. CastleArk Alternatives LLC acquired a new position in CareDx in the 3rd quarter valued at $4,545,000. Polar Asset Management Partners Inc. raised its stake in CareDx by 89.9% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 166,145 shares of the company’s stock valued at $10,529,000 after purchasing an additional 78,645 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of CareDx by 650.1% during the third quarter. Cubist Systematic Strategies LLC now owns 39,900 shares of the company’s stock worth $2,528,000 after buying an additional 34,581 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of CareDx in the third quarter worth about $385,000.

CareDx Company Profile (Get Rating)

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Recommended Stories

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.